Beam Therapeutics (BEAM) shares rose about 8% in recent trading Wednesday. Leerink Partners upgraded the company's stock to outperform from market perform and adjusted price target upwards to $39 from $27.
Trading volume stood at 1.25 million shares, against a daily average of 845,000.
Price: 25.81, Change: +1.88, Percent Change: +7.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments